<?xml version="1.0" encoding="UTF-8"?>
<p>In the next series of experiments, we tested two additional SAgs, namely MAM and SEA, in our model. MAM is produced by 
 <italic>Mycoplasma arthritidis</italic>, which is fundamentally different from 
 <italic>S</italic>. 
 <italic>aureus</italic> in terms of structural and genomic complexity, tissue tropism, and pathogenicity [
 <xref rid="ppat.1008393.ref062" ref-type="bibr">62</xref>]. This SAg offers two additional advantages. First, it has a relatively high affinity for mouse MHC molecules [
 <xref rid="ppat.1008393.ref063" ref-type="bibr">63</xref>]. Second, it binds to Vβ8.1–3 in BALB/c mice [
 <xref rid="ppat.1008393.ref063" ref-type="bibr">63</xref>], the main Vβ families utilized by NP
 <sub>147</sub>- and HA
 <sub>518</sub>-specific cells (
 <xref ref-type="fig" rid="ppat.1008393.g002">Fig 2A</xref>). These features provided us with a unique opportunity not only to extend our work beyond testing a single SAg (
 <italic>i</italic>.
 <italic>e</italic>., SEB) but also to solidify our conclusion that SAgs expand IAV-specific T
 <sub>CD8</sub> in a TCR Vβ-specific fashion. As hypothesized, pre-exposure to MAM selectively enhanced NP
 <sub>147</sub>- and HA
 <sub>518</sub>-specific responses (
 <xref ref-type="fig" rid="ppat.1008393.g002">Fig 2D</xref>), which mirrored our findings in SEB-pretreated mice (
 <xref ref-type="fig" rid="ppat.1008393.g001">Fig 1F</xref>).
</p>
